Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by…
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test…
Aon’s 2025 Global Cyber Risk Report Reveals Reputation Risk Events Can Reduce Shareholder Value by 27 percent
DUBLIN, June 17, 2025 /PRNewswire/ --Â Aon plc (NYSE: AON), a leading global…